Alnylam Pharmaceuticals
ALNY
#630
Rank
โ‚น2.815 T
Marketcap
โ‚น21,748
Share price
0.20%
Change (1 day)
75.40%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Earnings for Alnylam Pharmaceuticals (ALNY)

Earnings in 2024 (TTM): -โ‚น20.04 Billion

According to Alnylam Pharmaceuticals 's latest financial reports the company's current earnings are โ‚น2.24 Billion. , an increase over its 2023 earnings that were of -โ‚น27.06 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Alnylam Pharmaceuticals from 2003 to 2024

Annual earnings

Year Earnings Change
2024 -โ‚น20.41 Billion-24.59%
2023 -โ‚น27.06 Billion-67.84%
2022 -โ‚น84.14 Billion36.93%
2021 -โ‚น61.45 Billion-8.04%
2020 -โ‚น66.82 Billion-15.66%
2019 -โ‚น79.23 Billion12.23%
2018 -โ‚น70.59 Billion62.91%
2017 -โ‚น43.34 Billion17.78%
2016 -โ‚น36.79 Billion43.44%
2015 -โ‚น25.65 Billion60.69%
2014 -โ‚น15.97 Billion98.2%
2013 -โ‚น8.06 Billion
2011 -โ‚น4.75 Billion27.48%
2010 -โ‚น3.73 Billion-10.92%
2009 -โ‚น4.19 Billion95.77%
2008 -โ‚น2.14 Billion
2006 -โ‚น3.43 Billion-9.13%
2005 -โ‚น3.77 Billion34.74%
2004 -โ‚น2.8 Billion36.79%
2003 -โ‚น2.05 Billion

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
-โ‚น52.01 Billion 154.87%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น414.15 B-2,129.54%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น11.21 B-154.94%๐Ÿ‡บ๐Ÿ‡ธ USA
-โ‚น10.22 Billion-49.96%๐Ÿ‡บ๐Ÿ‡ธ USA
-โ‚น3.59 Billion-82.43%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น1.181 T-5,891.51%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
โ‚น641.85 B-3,245.35%๐Ÿ‡ซ๐Ÿ‡ท France
-โ‚น24.44 Billion 19.74%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel